Vision was improving in patients who had never seen improvement before
For the twenty million Americans whose central vision has quietly dimmed with age, macular degeneration has long represented a one-way door — sight lost, never recovered. Now, a small but striking clinical trial at the University of Michigan has cracked that door open: six patients with advanced dry AMD received transplanted adult stem cells and, one year later, could read letters they could not read before. It is early, and science demands patience, but the possibility of restoration — not merely delay — has entered the conversation for the first time.
- Dry AMD robs 20 million Americans of their central vision with no existing treatment capable of giving any of it back — until now.
- Six patients in a first-of-its-kind trial gained the ability to read 21 additional eye chart letters within a year, a result that had never been documented in this population before.
- The treated eyes improved while untreated eyes in the same patients did not, pointing directly to the transplant as the cause rather than chance or placebo.
- Researchers are now watching twelve more patients who received higher cell doses, holding the next phase of the trial in careful suspension until safety is confirmed.
- The field of regenerative ophthalmology, long theoretical, is now navigating its first credible evidence that lost retinal function may be recoverable.
Six patients with advanced dry macular degeneration underwent a procedure at the University of Michigan that most people in their position had stopped imagining: surgery with the potential to restore what the disease had taken. Researchers transplanted adult stem cells sourced from donated eye tissue directly into damaged retinas, targeting the retinal pigment epithelial cells whose death drives the dry form of AMD. The results, published in Cell Stem Cell, were unlike anything previously recorded for this patient group.
Dry AMD is the dominant form of the leading cause of permanent vision loss in Americans over 60. It destroys the macula — the small region of the retina responsible for sharp, central sight — leaving people unable to see faces, read text, or perceive the fine details of daily life, while their peripheral vision survives intact. No existing therapy can reverse this damage; the best available treatments only slow its progression.
The first six trial participants received the lowest dose tested: 50,000 transplanted cells per eye. The surgery was safe — no inflammation, no tumors, no serious complications. But one year later, those treated eyes had gained measurable vision. The patients could read 21 more letters on a standard eye chart than before. Their untreated eyes showed no comparable change, lending weight to the conclusion that the transplant itself drove the improvement. Lead ophthalmologist Rajesh C. Rao described being genuinely surprised by the magnitude of the effect, especially in the most severely affected patients.
The trial has since moved to higher-dose groups — 150,000 and 250,000 cells — with twelve additional participants now being monitored. If safety holds, researchers plan to advance into later trial phases. Funded by the National Institutes of Health, the work represents regenerative medicine moving from hypothesis toward clinical reality, and for millions living with fading central vision, it marks the first moment that restoration has seemed like a question worth asking.
Six people with advanced dry macular degeneration sat down for eye surgery at the University of Michigan and walked out with something they thought they'd lost forever: the possibility of seeing better. In a first-of-its-kind clinical trial, researchers transplanted adult stem cells derived from donated eye tissue directly into the retinas of patients whose vision had already begun to fail. The results, published in Cell Stem Cell, showed something that had never been documented before in this patient population—measurable vision improvement, not just slowing of decline.
Age-related macular degeneration is the leading cause of permanent vision loss in Americans over 60. Twenty million people in the country live with some form of it. The disease attacks the macula, a small but densely packed cluster of cells at the back of the eye responsible for sharp, detailed central vision. People with AMD lose the ability to see what's directly in front of them—faces, words on a page, the details that make up daily life—though their peripheral vision remains. It comes in two forms: wet and dry. More than 90 percent of patients have the dry type, which develops when the retinal pigment epithelial cells that support the macula begin to malfunction and eventually die. Once those cells are gone, they don't come back. Current treatments can slow the disease's progression, but none can restore what has already been lost.
The trial used a different approach. Researchers took adult stem cells from eye-bank tissue—cells with limited function that could only mature into retinal pigment epithelial cells—and transplanted them into the damaged retinas. The first group of six participants received the lowest dose: 50,000 cells per eye. The surgery itself proved safe. No serious inflammation occurred. No tumors grew. The patients healed without major complications.
But something unexpected happened. One year after the procedure, the treated eyes showed measurable improvement. The six patients could read 21 additional letters on a standard eye chart—a gain that had never been observed in advanced dry AMD patients before. Their untreated eyes showed no such change, which suggested the improvement came from the transplant itself, not from natural variation or placebo effect. Rajesh C. Rao, the ophthalmologist leading the work, described being surprised by the magnitude of the effect, particularly in the most severely affected patients. "We were pleased with the safety data," he said, "but the exciting part was that their vision was also improving."
The trial is now in its next phase. Twelve additional participants are being monitored after receiving higher doses—150,000 and 250,000 cells. If those patients tolerate the treatment without safety concerns, the research team plans to move forward into later stages of the clinical trial. The work is funded by the National Institutes of Health and represents the kind of regenerative medicine approach that has long been theoretical in ophthalmology. For millions of Americans whose central vision has already begun to fade, the question now is whether this early promise will hold.
Notable Quotes
We were surprised by the magnitude of vision gain in the most severely affected patients who received the adult stem cell-derived RPE transplants. This level of vision gain has not been seen in this group of patients with advanced dry AMD.— Rajesh C. Rao, ophthalmologist leading the trial
The Hearth Conversation Another angle on the story
Why does this matter so much? Vision loss is sad, but there are other treatments for AMD.
The other treatments only slow the disease. They can't bring back sight that's already gone. This is the first time anyone has shown you can actually restore vision in advanced cases.
So these six people—they were already severely affected?
Yes. They had advanced dry AMD. Their central vision was already significantly damaged. That's why the 21 additional letters they could read is so striking. In this patient group, you don't usually see gains at all.
Where did the stem cells come from?
Donated eye tissue. Adult stem cells, not embryonic. They were engineered to only become one type of cell—the retinal pigment epithelial cells that were dying in these patients' eyes.
And they just transplanted them directly into the eye?
Yes, during surgery. Six patients got 50,000 cells. No serious complications. That's the safety part. But then the vision actually improved, which nobody expected.
What happens next?
They're testing higher doses now with more patients. If those go well, the trial moves to the next phase. The real question is whether this holds up and whether it works for more people.